Intervention
Finerenone (nonsteroidal mineralocorticoid receptor antagonist)
Intervention
Moderate
Consistent
4 studies · 4 RCTs
Outcome
Cardiovascular Risk
Outcome
Evidence Question
Does Finerenone (nonsteroidal mineralocorticoid receptor antagonist) affect Cardiovascular Risk?
Related to: Cardiovascular RiskShort answer
Current evidence does not establish a clear direction of effect for Cardiovascular Risk with Finerenone (nonsteroidal mineralocorticoid receptor antagonist).
How the evidence connects
Each connection shows the published evidence classification for that intervention and outcome relationship.